Register for free to
view the full innovation profile.
Repurposed antidepressant agents for treating levodopa-induced dyskinesia in Parkinson's disease
About
Binghamton University Professor Christopher Bishop has developed a new method for treating LID in Parkinson’s disease, demonstrating for the first time the anti-dyskinetic potential of dual partial 5-HT1A agonist/SSRI agents, including the FDA-approved antidepressants vilazodone (Viibryd) and vortioxetine (Trintellix). The dual-activity antidepressants dramatically reduced LID and maintained these effects for several weeks without altering L-DOPA’s positive anti-parkinsonian effects.
Key Benefits
More effective than currently approved therapy; Potent and stable response; Reduced side effect profile; FDA-approved compounds positioned for rapid repurposing; Effective in prevention and treatment of LID in Parkinson’s patients.
Applications
Treatment of L-DOPA-induced dyskinesia in Parkinson’s disease patients.